ストックスクリーナーアプリを入手
60.22
0.89%
0.53
プレマーケット:
60.80
0.58
+0.96%
前日終値:
$59.69
開ける：
$60
24時間の取引高:
536.01K
Relative Volume:
0.32
時価総額：
$6.46B
収益：
$769.10M
当期純損益:
$46.67M
株価収益率:
172.06
EPS:
0.35
ネットキャッシュフロー:
$119.79M
1週間 パフォーマンス:
+6.83%
1か月 パフォーマンス:
+29.31%
6か月 パフォーマンス:
-22.09%
1年 パフォーマンス:
-20.86%
1日の値動き範囲:
$59.54
$60.95
1週間の範囲:
$54.59
$60.95
52週間の値動き範囲:
$28.66
$91.00
Corcept Therapeutics Inc Stock (CORT) Company Profile
名前
Corcept Therapeutics Inc
セクター
電話
650.688.8803
住所
101 REDWOOD SHORES PARKWAY, REDWOOD CITY
Compare CORT vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CORT
Corcept Therapeutics Inc
|
60.22 | 6.41B | 769.10M | 46.67M | 119.79M | 0.35 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Corcept Therapeutics Inc Stock (CORT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-26 | アップグレード | Wolfe Research | Underperform → Peer Perform |
| 2025-12-31 | ダウングレード | Wolfe Research | Peer Perform → Underperform |
| 2025-12-16 | 開始されました | UBS | Neutral |
| 2025-11-18 | 開始されました | Wolfe Research | Peer Perform |
| 2023-11-06 | アップグレード | Truist | Hold → Buy |
| 2023-04-11 | 開始されました | SVB Securities | Market Perform |
| 2023-04-04 | 開始されました | Piper Sandler | Overweight |
| 2023-02-15 | ダウングレード | Jefferies | Buy → Hold |
| 2022-08-01 | ダウングレード | Truist | Buy → Hold |
| 2022-07-27 | アップグレード | Jefferies | Hold → Buy |
| 2022-06-27 | 再開されました | Canaccord Genuity | Buy |
| 2022-02-02 | 開始されました | Canaccord Genuity | Buy |
| 2022-01-28 | 開始されました | Truist | Buy |
| 2020-08-05 | ダウングレード | Jefferies | Buy → Hold |
| 2019-09-24 | 開始されました | Jefferies | Buy |
| 2019-09-06 | 開始されました | H.C. Wainwright | Buy |
| 2019-02-04 | ダウングレード | B. Riley FBR | Buy → Neutral |
| 2018-08-10 | 繰り返されました | Stifel | Hold |
| 2018-05-31 | ダウングレード | Stifel | Buy → Hold |
| 2018-03-09 | 開始されました | B. Riley FBR, Inc. | Buy |
| 2017-08-31 | 開始されました | Stifel | Buy |
| 2017-02-02 | 開始されました | Ladenburg Thalmann | Buy |
| 2015-04-21 | 開始されました | FBR Capital | Outperform |
| 2014-01-13 | ダウングレード | Stifel | Buy → Hold |
| 2013-08-09 | ダウングレード | Janney | Buy → Neutral |
| 2013-08-09 | ダウングレード | Ladenburg Thalmann | Buy → Neutral |
| 2012-02-21 | 繰り返されました | JMP Securities | Mkt Outperform |
| 2010-01-06 | アップグレード | Ladenburg Thalmann | Neutral → Buy |
| 2008-07-17 | 開始されました | Rodman & Renshaw | Mkt Outperform |
| 2007-06-21 | アップグレード | Punk, Ziegel & Co | Mkt Perform → Accumulate |
すべてを表示
Corcept Therapeutics Inc (CORT) 最新ニュース
CORT Stock Price, Quote & Chart | CORCEPT THERAPEUTICS INC (NASDAQ:CORT) - ChartMill
Affiliate of CORT (NASDAQ: CORT) files Form 144 to offer 5,000 shares - Stock Titan
Wall Street Analysts Believe Corcept (CORT) Could Rally 43.32%: Here's is How to Trade - Yahoo Finance UK
Corcept Therapeutics Inc. (CORT) Stock Analysis: Exploring a 40.15% Potential Upside for Biotech Investors - DirectorsTalk Interviews
Corcept (CORT) chief business officer reports 7,300-share gift of common stock - Stock Titan
CORT Stock Chart | CORCEPT THERAPEUTICS INC (NASDAQ:CORT) - ChartMill
UBS upgrades Corcept Therapeutics (CORT) - MSN
Corcept Therapeutics (CORT) Receives Upgrade, Stock Surges Over 7% - GuruFocus
Corcept Therapeutics Shares Rise After UBS Upgrade - Moomoo
UBS Upgrades Corcept Therapeutics(CORT.US) to Buy Rating, Cuts Target Price to $72 - Moomoo
Corcept Therapeutics climbs on UBS upgrade - MSN
Corcept Therapeutics (CORT) Stock Analysis: Unveiling a 40% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
CORT Q1 earnings match estimates, revenues miss, 2026 outlook raised - MSN
Vanguard Group Inc. Has $330.42 Million Holdings in Corcept Therapeutics Incorporated $CORT - MarketBeat
Why Corcept Therapeutics Stock Is Sinking Now - TipRanks
CORT IMPORTANT DEADLINE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Corcept Therapeutics Incorporated Investors with Losses in Excess of $100K to Secure Counsel Before Important April 21 Deadline in Securities Class ActionCORT - TMX Newsfile
Corcept (CORT) CDO sells 20K shares under 10b5-1 plan - Stock Titan
CORT FINAL DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Corcept Therapeutics Incorporated Investors with Losses in Excess of $100K to Secure Counsel Before Important April 21 Deadline in Securities Class ActionCORT - TMX Newsfile
Corcept Therapeutics (CORT) Is Up 11.9% After Q1 Loss, Higher 2026 Outlook And ALS DataHas The Bull Case Changed? - Yahoo Finance
Corcept (CORT) Q1 2025 Earnings Transcript - AOL.com
Corcept Must Face Most Teva Mifepristone Antitrust Claims - Law360
Corcept Therapeutics IncorporatedCommon Stock (NQ: CORT - FinancialContent
How many employees work at Corcept Therapeutics? - Revelio Labs
Teva's US exclusive-dealing claims survive Corcept's move to dismiss - MLex
Corcept (NASDAQ: CORT) CEO sells 40K shares under 10b5-1 plan - Stock Titan
Corcept Therapeutics (NASDAQ: CORT) affiliate plans sale of 20,000 shares via Stifel - Stock Titan
Corcept Therapeutics Incorporated (NASDAQ:CORT) Q1 2026 Earnings Call Transcript - Insider Monkey
CORT Q1 Deep Dive: Early Lifyorli Launch and Endocrinology Momentum Offset Margin Pressures - Yahoo Finance
Corcept (CORT) Q1 2026 Earnings Transcript - AOL.com
Corcept Therapeutics Is Maintained at Buy by HC Wainwright & Co. - Moomoo
CCORF Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Maintains Target Price $110 - Moomoo
Corcept (CORT) Q2 2025 Earnings Transcript - AOL.com
Corcept (CORT) Q4 2025 Earnings Transcript - AOL.com
CORT Maintained by HC Wainwright & Co. -- Price Target Raised to $75 - GuruFocus
CORT DEADLINE: ROSEN, A LEADING AND TOP RANKED LAW FIRM, Encourages Corcept Therapeutics Incorporated Investors with Losses in Excess of $100K to Secure Counsel Before Important April 21 Deadline in Securities Class ActionCORT - TMX Newsfile
Corcept Therapeutics Inc. (CORT) Stock Analysis: A 36.91% Upside Potential In Biotech - DirectorsTalk Interviews
MSN Money - MSN
symbol__ Stock Quote Price and Forecast - CNN
Corcept (CORT) Upgraded After Key Regulatory Approval for Lifyorli - Yahoo Finance
Corcept Therapeutics Shakes Up Nasdaq Index Fund Radar - Kalkine Media
CORT Maintained by Piper Sandler -- Price Target Raised to $88 - GuruFocus
Corcept Therapeutics Guides Higher on Lifyorli-Fueled Revenue Growth - The Globe and Mail
Corcept Therapeutics Is Maintained at Overweight by Piper Sandler - Moomoo
Corcept Therapeutics (NASDAQ:CORT) Stock Price Up 7.9%Time to Buy? - MarketBeat
Corcept Therapeutics (CORT) insider notifies sale of 40,000 shares via Stifel - Stock Titan
CORT Q1 Earnings Match Estimates, Revenues Miss, 2026 Outlook Raised - The Globe and Mail
Corcept Therapeutics Pivotal Study Shows 87% Lower Death Risk - Benzinga
Corcept Therapeutics Incorporated Q1 2026 Earnings Call Summary - Yahoo Finance
Corcept Therapeutics Inc (CORT) Q1 2026 Earnings Call Highlights - GuruFocus
Corcept Therapeutics Inc (CORT) 財務データ
収益
当期純利益
現金流量
EPS
2.98%
1.33%
大文字化:
|
ボリューム (24 時間):